Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -701.21 Thousand CAD | 15.17% |
| 2022 | -826.59 Thousand CAD | 52.67% |
| 2021 | -1.74 Million CAD | -31.03% |
| 2020 | -1.33 Million CAD | 36.91% |
| 2019 | -2.11 Million CAD | 60.81% |
| 2018 | -5.39 Million CAD | -54.65% |
| 2017 | -3.48 Million CAD | -33.38% |
| 2016 | -2.61 Million CAD | -18.78% |
| 2015 | -2.2 Million CAD | -199.84% |
| 2014 | -733.94 Thousand CAD | -358.95% |
| 2013 | 283.43 Thousand CAD | 192.45% |
| 2012 | -306.56 Thousand CAD | 83.65% |
| 2011 | -1.87 Million CAD | 53.02% |
| 2010 | -3.99 Million CAD | -237.5% |
| 2009 | -1.18 Million CAD | 38.95% |
| 2008 | -1.93 Million CAD | -244.74% |
| 2007 | -562.09 Thousand CAD | -48.58% |
| 2006 | -378.3 Thousand CAD | 52.49% |
| 2005 | -796.3 Thousand CAD | -8.86% |
| 2004 | -731.47 Thousand CAD | -1267.79% |
| 2003 | -53.47 Thousand CAD | 23.15% |
| 2002 | -69.59 Thousand CAD | -454.46% |
| 2001 | -12.55 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 54.02 Thousand CAD | -67.95% |
| 2024 Q1 | 168.53 Thousand CAD | 182.86% |
| 2023 Q2 | -284.22 Thousand CAD | -48.41% |
| 2023 Q4 | 59.58 Thousand CAD | 120.9% |
| 2023 Q3 | -285.06 Thousand CAD | -0.29% |
| 2023 FY | -701.21 Thousand CAD | 15.17% |
| 2023 Q1 | -191.51 Thousand CAD | 24.1% |
| 2022 FY | -826.59 Thousand CAD | 52.67% |
| 2022 Q1 | -186.74 Thousand CAD | 10.6% |
| 2022 Q2 | -206.25 Thousand CAD | -10.45% |
| 2022 Q3 | -179.54 Thousand CAD | 12.95% |
| 2022 Q4 | -252.33 Thousand CAD | -40.54% |
| 2021 Q2 | -344.62 Thousand CAD | 51.82% |
| 2021 FY | -1.74 Million CAD | -31.03% |
| 2021 Q3 | -439.31 Thousand CAD | -27.48% |
| 2021 Q4 | -208.89 Thousand CAD | 52.45% |
| 2021 Q1 | -715.3 Thousand CAD | -32.83% |
| 2020 FY | -1.33 Million CAD | 36.91% |
| 2020 Q4 | -538.49 Thousand CAD | -160.41% |
| 2020 Q3 | -206.78 Thousand CAD | -4.38% |
| 2020 Q2 | -198.11 Thousand CAD | 14.07% |
| 2020 Q1 | -230.56 Thousand CAD | 24.59% |
| 2019 FY | -2.11 Million CAD | 60.81% |
| 2019 Q3 | -683.42 Thousand CAD | -28.64% |
| 2019 Q2 | -531.28 Thousand CAD | 9.2% |
| 2019 Q1 | -585.13 Thousand CAD | 70.29% |
| 2019 Q4 | -305.75 Thousand CAD | 55.26% |
| 2018 FY | -5.39 Million CAD | -54.65% |
| 2018 Q4 | -1.96 Million CAD | -188.41% |
| 2018 Q3 | -682.79 Thousand CAD | 14.74% |
| 2018 Q2 | -800.8 Thousand CAD | -17.08% |
| 2018 Q1 | -683.96 Thousand CAD | 31.19% |
| 2017 Q3 | -599.98 Thousand CAD | -42.89% |
| 2017 FY | -3.48 Million CAD | -33.38% |
| 2017 Q1 | -722.79 Thousand CAD | 27.94% |
| 2017 Q2 | -419.89 Thousand CAD | 41.91% |
| 2017 Q4 | -994.04 Thousand CAD | -65.68% |
| 2016 Q1 | -708.82 Thousand CAD | -10.45% |
| 2016 FY | -2.61 Million CAD | -18.78% |
| 2016 Q2 | -587.81 Thousand CAD | 17.07% |
| 2016 Q4 | -1 Million CAD | -219.27% |
| 2016 Q3 | -314.18 Thousand CAD | 46.55% |
| 2015 FY | -2.2 Million CAD | -199.84% |
| 2015 Q4 | -641.75 Thousand CAD | -16.97% |
| 2015 Q1 | -461.09 Thousand CAD | -12.01% |
| 2015 Q2 | -1.16 Million CAD | -153.35% |
| 2015 Q3 | -548.66 Thousand CAD | 53.03% |
| 2014 Q3 | -157.6 Thousand CAD | 33.4% |
| 2014 Q2 | -236.64 Thousand CAD | -0.92% |
| 2014 Q1 | -234.48 Thousand CAD | -111.01% |
| 2014 FY | -733.94 Thousand CAD | -358.95% |
| 2014 Q4 | -411.65 Thousand CAD | -161.19% |
| 2013 Q3 | -150.33 Thousand CAD | 71.16% |
| 2013 Q1 | -45.39 Thousand CAD | -49.34% |
| 2013 Q2 | -521.29 Thousand CAD | -1048.41% |
| 2013 Q4 | -111.12 Thousand CAD | 26.08% |
| 2013 FY | 283.43 Thousand CAD | 192.45% |
| 2012 FY | -306.56 Thousand CAD | 83.65% |
| 2012 Q2 | -110.61 Thousand CAD | -302.07% |
| 2012 Q3 | 880.51 Thousand CAD | 896.02% |
| 2012 Q4 | -30.39 Thousand CAD | -103.45% |
| 2012 Q1 | 54.74 Thousand CAD | 181.16% |
| 2011 Q1 | -262.71 Thousand CAD | 73.41% |
| 2011 FY | -1.87 Million CAD | 53.02% |
| 2011 Q3 | -183.24 Thousand CAD | 80.75% |
| 2011 Q4 | -67.45 Thousand CAD | 63.19% |
| 2011 Q2 | -952.04 Thousand CAD | -262.39% |
| 2010 Q2 | -1.28 Million CAD | 24.94% |
| 2010 Q3 | -335.44 Thousand CAD | 73.96% |
| 2010 Q1 | -1.71 Million CAD | -408.16% |
| 2010 Q4 | -988.01 Thousand CAD | -194.54% |
| 2010 FY | -3.99 Million CAD | -237.5% |
| 2009 Q1 | -219.01 Thousand CAD | 22.56% |
| 2009 Q2 | -417.33 Thousand CAD | -90.55% |
| 2009 Q3 | -650.26 Thousand CAD | -55.82% |
| 2009 Q4 | -337.75 Thousand CAD | 48.06% |
| 2009 FY | -1.18 Million CAD | 38.95% |
| 2008 FY | -1.93 Million CAD | -244.74% |
| 2008 Q4 | -282.8 Thousand CAD | -7.18% |
| 2008 Q3 | -263.86 Thousand CAD | 71.68% |
| 2008 Q2 | -931.59 Thousand CAD | -199.65% |
| 2008 Q1 | -310.89 Thousand CAD | 44.89% |
| 2007 Q3 | -131.08 Thousand CAD | 53.28% |
| 2007 Q2 | -280.58 Thousand CAD | -226.03% |
| 2007 Q1 | -86.06 Thousand CAD | 4.57% |
| 2007 Q4 | -564.16 Thousand CAD | -330.38% |
| 2007 FY | -562.09 Thousand CAD | -48.58% |
| 2006 Q4 | -90.18 Thousand CAD | 14.33% |
| 2006 Q1 | -118.08 Thousand CAD | 13.94% |
| 2006 Q2 | -67.36 Thousand CAD | 42.95% |
| 2006 Q3 | -105.26 Thousand CAD | -56.25% |
| 2006 FY | -378.3 Thousand CAD | 52.49% |
| 2005 Q1 | -134.63 Thousand CAD | 10.27% |
| 2005 Q2 | -371.22 Thousand CAD | -175.72% |
| 2005 Q3 | -55.63 Thousand CAD | 85.01% |
| 2005 Q4 | -137.21 Thousand CAD | -146.64% |
| 2005 FY | -796.3 Thousand CAD | -8.86% |
| 2004 FY | -731.47 Thousand CAD | -1267.79% |
| 2004 Q4 | -150.04 Thousand CAD | -6.63% |
| 2004 Q3 | -140.71 Thousand CAD | 65.31% |
| 2004 Q2 | -405.64 Thousand CAD | -110.84% |
| 2004 Q1 | -192.39 Thousand CAD | -56.69% |
| 2003 Q1 | -11.51 Thousand CAD | 30.14% |
| 2003 Q4 | -122.78 Thousand CAD | -1051.36% |
| 2003 Q3 | -10.66 Thousand CAD | 41.76% |
| 2003 FY | -53.47 Thousand CAD | 23.15% |
| 2003 Q2 | -18.31 Thousand CAD | -59.0% |
| 2002 Q4 | -16.48 Thousand CAD | -130.12% |
| 2002 FY | -69.59 Thousand CAD | -454.46% |
| 2002 Q3 | -7164.00 CAD | 0.0% |
| 2001 FY | -12.55 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 50.268% |
| Arrayit Corporation | -3.31 Million USD | 78.851% |
| Atlantic International Corp. | -5.62 Million USD | 87.54% |
| Biocept, Inc. | -32.08 Million USD | 97.815% |
| Bioqual, Inc. | 483.48 Thousand USD | 245.035% |
| CardioGenics Holdings Inc | -1.91 Million USD | 63.408% |
| DermTech, Inc. | -100.88 Million USD | 99.305% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.035% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 96.753% |
| iMD Companies, Inc. | -200.63 Thousand USD | -249.496% |
| IDenta Corp. | 14.64 Thousand USD | 4888.412% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 187.433% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 1912.44% |
| InVitro International | 1553.00 USD | 45252.286% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 91.839% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -1106.661% |
| Medical Imaging Corp. | -3.02 Million USD | 76.804% |
| NovelStem International Corp. | -4.18 Million USD | 83.254% |
| Optigenex Inc. | -2.89 Million USD | 75.801% |
| PharmChem, Inc. | 845.1 Thousand USD | 182.974% |
| Proteome Sciences plc | -2.44 Million USD | 71.297% |
| Response Genetics, Inc | -20.18 Million USD | 96.526% |
| Rennova Health, Inc. | -3.29 Million USD | 78.706% |
| RushNet, Inc. | -607.02 Thousand USD | -15.516% |
| ScreenPro Security Inc. | -2.24 Million USD | 68.818% |
| Stella Diagnostics Inc. | -5.7 Million USD | 87.714% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 93.857% |
| Todos Medical Ltd. | -24.99 Million USD | 97.194% |